A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease

2016 ◽  
Vol 21 (1) ◽  
pp. 72-83 ◽  
Author(s):  
Hiroyuki Kamiya
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor

Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials

Nephron ◽  
2017 ◽  
Vol 136 (2) ◽  
pp. 85-94 ◽  
Author(s):  
Simon R. Walker ◽  
Paul Komenda ◽  
Suhail Khojah ◽  
Wafa Al-Tuwaijri ◽  
Kerry MacDonald ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Clinical Trials ◽  
Kidney Disease ◽  
Randomized Clinical Trials ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals The dipeptidyl peptidase-4 inhibitor teneligliptin reduces kidney damage from hypercholesterolemia in apolipoprotein E-deficient mice

RSC Advances ◽  
2017 ◽  
Vol 7 (14) ◽  
pp. 8702-8708 ◽  
Author(s):  
Hui Liu ◽  
Nan Li ◽  
Ying Liu ◽  
Jing Xing ◽  
Shuai Feng ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Risk Factor ◽  
Kidney Disease ◽  
Apolipoprotein E ◽  
Kidney Injury ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Established Risk Factor ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Deficient Mice

Hypercholesterolemia is a well-established risk factor for kidney injury that can lead to chronic kidney disease (CKD).

Sign in / Sign up

Export Citation Format

Share Document